STOCK TITAN

Processa Pharmaceuticals, Inc. (PCSA) CFO awarded 11,883 RSUs and holds options

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. reported that Chief Financial Officer Russell Skibsted received a grant of 11,883 Restricted Stock Units on July 26, 2026. These RSUs vested immediately but will be settled later under specified conditions. After the grant he directly holds 17,323 RSUs, 16,689 common shares and stock options over 12,960 shares at a $4.9600 exercise price.

Positive

  • None.

Negative

  • None.
Insider SKIBSTED RUSSELL
Role Chief Financial Officer
Type Security Shares Price Value
Grant/Award Restricted Stock Units F1, F3 11,883 $0.00 $0.00
holding Stock Options (Right to Buy) F2, F3 -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Restricted Stock Units — 17,323 shares (Direct); Stock Options (Right to Buy) — 12,960 shares (Direct); Common Stock — 16,689 shares (Direct)
Footnotes (3)
  1. F1. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.
  2. F2. Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.
  3. F3. Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.
RSU grant 11883.0000 Restricted Stock Units Granted to the Chief Financial Officer on July 26, 2026
RSUs held after grant 17323.0000 Restricted Stock Units Total direct RSU holdings after the reported acquisition
Stock options underlying shares 12960.0000 shares Underlying common shares subject to stock options held directly
Stock option exercise price $4.9600 per share Exercise price for stock options over 12,960 underlying shares
Common stock held directly 16689.0000 shares Direct holdings of Processa Pharmaceuticals common stock after transactions
Reverse stock split ratio 1-for-25 Reverse stock split effected on December 17, 2025, reflected in reported amounts
Restricted Stock Units financial
"Each Restricted Stock Unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Options (Right to Buy) financial
"Stock Options (Right to Buy) with an exercise price of 4.9600"
1-for-25 reverse stock split financial
"Reflects the 1-for-25 reverse stock split effected by the Issuer"
change of control financial
"distributed until the earlier of termination, six months, change of control, or death"
A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What equity award did PCSA’s Chief Financial Officer receive in this Form 4?

Russell Skibsted, CFO of PCSA, received a grant of 11,883 Restricted Stock Units on July 26, 2026. Each RSU represents a contingent right to receive one share of Processa Pharmaceuticals common stock, increasing his overall equity-based compensation position.

How do the RSUs granted to PCSA’s CFO vest and when will they be distributed?

The 11,883 RSUs vested upon grant but are not distributed immediately. Shares will be delivered at the earlier of termination, six months after the grant date, a change of control, or the CFO’s death, creating a deferred-settlement equity award.

What stock option position does the PCSA CFO hold after the reported transactions?

After the reported transactions, the CFO holds stock options over 12,960 underlying common shares with a $4.9600 exercise price. These options vest one-third on the first anniversary of the grant, with the remaining options vesting ratably over the subsequent two years.

How many PCSA common shares and RSUs does the CFO directly hold following this grant?

Following the RSU grant, the CFO directly holds 16,689 common shares of Processa Pharmaceuticals and 17,323 Restricted Stock Units. This reflects his updated direct ownership in both actual shares and deferred equity units tied to the company’s common stock.

What is the 1-for-25 reverse stock split mentioned for PCSA in this filing?

The footnotes state that figures reflect a 1-for-25 reverse stock split effected on December 17, 2025. This corporate action consolidated every 25 existing shares into one, and the reported RSU, option, and share amounts are already adjusted for that split.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SKIBSTED RUSSELL

(Last)(First)(Middle)
C/O PROCESSA PHARMACEUTICALS, INC.
601 21ST STREET SUITE 300

(Street)
VERO BEACH FLORIDA 32960

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/26/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock16,689D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units$007/26/2026A11,883(1) (1) (1)Common Stock11,883$017,323(3)D
Stock Options (Right to Buy)$4.96 (2) (2)Common Stock12,96012,960(3)D
Explanation of Responses:
1. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.
2. Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.
3. Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.
/s/ Russell Skibsted by John J. Wolfel, as Attorney-in-Fact07/28/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)